Figure 5
Figure 5. ARC19499 effect on clot formation in FVIII antibody–treated whole blood. (A) Representative TEG tracings in untreated (left) and antibody-treated (right) whole blood. Black lines show untreated whole blood without aptamer; green, 1nM ARC19499; pink, 10nM ARC19499; red, 100nM ARC19499; and blue, antibody-treated whole blood without aptamer. (B) Effect of ARC19499 on TEG parameters of FVIII antibody–treated whole blood. Left panel shows the R value; middle, angle; right, MA. Lines represent the activity of untreated (dashed lines) and antibody-treated (solid lines) whole blood in the absence of aptamer, with the shaded areas representing SEM. Results are represented as the means ± SEM; n = 3.

ARC19499 effect on clot formation in FVIII antibody–treated whole blood. (A) Representative TEG tracings in untreated (left) and antibody-treated (right) whole blood. Black lines show untreated whole blood without aptamer; green, 1nM ARC19499; pink, 10nM ARC19499; red, 100nM ARC19499; and blue, antibody-treated whole blood without aptamer. (B) Effect of ARC19499 on TEG parameters of FVIII antibody–treated whole blood. Left panel shows the R value; middle, angle; right, MA. Lines represent the activity of untreated (dashed lines) and antibody-treated (solid lines) whole blood in the absence of aptamer, with the shaded areas representing SEM. Results are represented as the means ± SEM; n = 3.

Close Modal

or Create an Account

Close Modal
Close Modal